本研究在体证实了MSA中存在胆碱能通路特异性损伤，尤其PPN-丘脑通路作为运动调控关键枢纽，其损伤程度与疾病严重度密切关联。该发现不仅深化了对MSA病理机制的理解，也为未来开发胆碱能通路靶向治疗策略提供了影像学依据。团队下一步将推进多中心纵向研究，验 ...

MSA作为一种进展性神经退行性疾病，其病理核心为α-突触核蛋白在少突胶质细胞中异常沉积形成的胶质胞质包涵体。既往尸检研究提示脑干脚桥核（PPN）和基底前脑Meynert核（NBM）的胆碱能神经元显著丢失，但对其投射通路的在体评估及临床关联仍缺乏系统研究。 团队纳入103例MSA患者与44名健康对照者，通过多模态磁共振数据重建三条关键胆碱能通路：NBM-内侧皮层通路（经扣带回）、NBM-外侧皮层通路 ...

NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in ...

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th ...

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...

VALBY, Denmark, Oct. 2, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of ...